JDHMAIN JDH Futures(OCT4)
- 26.03
- -0.06-0.23%
JDH Futures(OCT4) News
JD Health (6618.HK): Restoring solid consumer demand will take time
JD Health (06618.HK): Strong profit side performance, high quality and steady growth
JD Health (06618.HK): 24H1 Performance Review: Profit side creates new high quality development for half a year and consolidates leading edge
JD Health (06618.HK): The company's revenue growth is steady and profit performance is impressive
JD HEALTH(6618.HK):MIXED 1H24;COMMITTED STRATEGIES AMID POST-COVID ERA
JD Health (6618.HK): Profit side exceeds expectations and has sufficient cash reserves
JD Health (6618.HK): The margins between merchants and users from the three parties are improving
Morgan Stanley Downgrades JD Health International to Underweight From Equal-weight; Price Target Is HK$20.40
JD Health (06618.HK): The impact of the high base figure is nearing its end, pay attention to signs of fundamental recovery throughout the year
JD Health (06618.HK): Three-party merchant ecosystem construction accelerates full coverage of online and offline medical scenarios
JD Health (6618.HK): Gross margin is expected to continue to recover, and service revenue is expected to maintain rapid growth
JD Health (06618.HK) 2023 Annual Report Performance Review: Reducing Costs and Increasing Efficiency to Develop New Quality Productivity Layout Medical Services
JD Health (6618.HK): Expanding the Tripartite Merchant Ecosystem to Help Return to an Endogenous Growth Path
JD Health (6618.HK) 2023 Report Review: The number of merchants on the three sides increased dramatically, and the big model helped reduce costs and increase efficiency
JD Health (6618.HK): Performance growth exceeds expectations, omnichannel business layout accelerates
Nomura Adjusts JD Health's Price Target to HK$44 to HK$37, Keeps at Buy
JD Health (06618.HK): Focus on the impact of a high base on growth performance in 2024 after clearing
Changes in Hong Kong stocks | JD Health (06618) rose more than 7% in the intraday period, institutions are optimistic about the company's revenue prospects, rising earnings estimates and target prices
Bank of America Ratings | Bank of America: Reiterates JD Health's “Buy” Rating Upgrades Last Year's Revenue Forecast
Nomura Adjusts JD Health International's Price Target to HK$44 From HK$60, Keeps at Buy